Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06600906 · ClinicalTrials.gov registry record
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
A clinical trial of Pancreatic Ductal Adenocarcinoma and Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 70
- Enrollment target
- 1
- Study location
NCT06600906 is a study of Pancreatic Ductal Adenocarcinoma and Metastatic Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 70 participants, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06600906, a study of Pancreatic Ductal Adenocarcinoma and Metastatic Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates an investigational scan called hyperpolarized carbon-13 pyruvate magnetic resonance imaging (MRI) in assessing treatment response in patients with pancreatic ductal carcinoma (PDA) that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). MRI is a standard scan that helps doctors see tumors, organs, tissue, and bone. Standard contrast agents (e.g., gadolinium) are sometimes used to help make the scan images brighter, or easier to see. Hyperpolarized carbon-13 pyruvate is an experimental contrast agent that is different from standard MRI contrast in that it provides information on how a tumor processes nutrients. Hyperpolarized carbon-13 pyruvate MRI scans may work better than MRI with standard contrast agents in predicting how PDA tumors respond to treatment.
Conditions Studied
Interventions
- DRUG Hyperpolarized 13C-Pyruvate
- PROCEDURE Magnetic Resonance Imaging (MRI)
- PROCEDURE Computed tomography (CT)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2032-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06600906
The ClinicalTrials.gov registry entry for NCT06600906 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (88% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Hyperpolarized 13C-Pyruvate is the first listed.
NCT06600906 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06600906 about?
NCT06600906 is a clinical study titled "Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer". This study evaluates an investigational scan called hyperpolarized carbon-13 pyruvate magnetic resonance imaging (MRI) in assessing treatment response in patients with pancreatic ductal carcinoma (PDA) that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where i...
What is the current status of trial NCT06600906?
This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2024-10-01. Estimated completion is 2032-09-01.
What conditions does trial NCT06600906 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT06600906?
The interventions under investigation include: Hyperpolarized 13C-Pyruvate (DRUG), Magnetic Resonance Imaging (MRI) (PROCEDURE), Computed tomography (CT) (PROCEDURE).
Who is sponsoring clinical trial NCT06600906?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06600906 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
RECRUITING
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Pancreatic Ductal Adenocarcinoma
All registered trials for this condition
Metastatic Pancreatic Ductal Adenocarcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.